Jiangxi Fushine Pharmaceutical Co., Ltd. (SHE:300497)

China flag China · Delayed Price · Currency is CNY
19.83
+0.63 (3.28%)
Apr 29, 2026, 3:13 PM CST
129.78%
Market Cap 10.68B
Revenue (ttm) 1.31B
Net Income (ttm) 3.93M
Shares Out 538.65M
EPS (ttm) 0.01
PE Ratio 2,717.12
Forward PE 15.37
Dividend n/a
Ex-Dividend Date n/a
Volume 63,186,355
Average Volume 60,187,329
Open 17.89
Previous Close 19.20
Day's Range 17.89 - 19.90
52-Week Range 8.23 - 22.63
Beta 0.43
RSI 61.07
Earnings Date Apr 28, 2026

About SHE:300497

Jiangxi Fushine Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of APIs and pharmaceutical intermediates in China and internationally. The company offers β-lactamase inhibitors, carbapenem antibiotics, and antiviral drug intermediates; argatroban injection for the treatment of acute ischemic stroke; and doxycycline hydrochloride dispersible tablets to treat rickettsial diseases, mycoplasmal and chlamydial infections, relapsing fever, brucellosis, cholera, tularemia, plague, an... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 1,774
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300497
Full Company Profile

Financial Performance

In 2025, SHE:300497's revenue was 1.18 billion, an increase of 0.61% compared to the previous year's 1.18 billion. Losses were -55.03 million, -79.78% less than in 2024.

Financial Statements

News

There is no news available yet.